Navigation Links
OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
Date:6/22/2011

SAN DIEGO, June 22, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), a therapeutic oncology company developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that Anthony E Maida, III, Ph.D., has been appointed to OncoSec's board of directors and will chair its audit committee.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

For over 20 years, Dr. Maida has focused on clinical development of immunotherapies to treat patients with cancer. As a Chairman, CEO and senior executive, Dr. Maida has managed and executed all critical functions, including finance, operations, research, clinical development, regulatory and manufacturing for biotechnology companies in early and late-stage development of cancer therapeutics. In addition, he has negotiated significant license agreements with numerous global pharmaceutical firms and major universities. Dr. Maida has also raised or assisted in financings of nearly $200 million for start-up and emerging biotechnology companies.

Dr. Maida stated, "OncoSec's novel approaches to addressing the challenge of treating solid tumors in a manner that is less invasive are very promising. I'm pleased to be able to offer my experience to OncoSec at a time when they are moving their oncology therapies into advanced clinical trials."

Punit Dhillon, OncoSec's President and CEO, said, "Dr. Maida's expertise could not be a better fit for OncoSec, its technology platform, and its development plans. We look forward to the critical input, guidance and resources he will be able to contribute to OncoSec and its shareholders."

Dr. Maida was recently Vice President of Clinical Research and General Manager, Oncology, World-wide, for a leading international contract research organization. Prior to this, Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street in the clinical development of therapeutic products and product/company acquisitions.

He was formerly President and CEO of Replicon NeuroTherapeutics, Inc., a biopharmaceutical company focused on therapies against primary and metastatic tumors of the central nervous system; interim CEO for Trellis Bioscience, Inc.; and President of CancerVax Corporation, where he completed the Company's first financing of $30 million. As President and CEO of Jenner Biotherapies, Inc., he oversaw the launch of multiple clinical studies, including late stage studies, of cancer therapeutics.

Today, Dr. Maida serves as an advisor, consultant and technical analyst for multiple investment firms and life science companies. He sits on the board of directors of Spectrum Pharmaceuticals, Inc. and is a former board member of Sirion Therapeutics, Inc. and GlycoMetrix, Inc.

Dr. Maida holds a B.A. in biology, B.A. in history, a M.B.A., a M.A. in toxicology, and Ph.D. in tumor immunology. He is a member of multiple professional associations including the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR). Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.

Dr. Maida joins a Board of experienced biotechnology executives (see Leadership profiles).

About OncoSec Medical Inc.

Oncosec Medical Incorporated (OTCBB: ONCS) develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Globus Medical Raises $110 Million in Series E Financing Round
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Boston University Biomedical Engineers Find Chink in Bacterias Armor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):